Abstract
When the transvenous ICD initially came into use for primary and secondary prevention of sudden cardiac death, defibrillation threshold (DFT) testing was universally performed. However, DFT testing is no longer routinely recommended for transvenous ICD implantation except in certain situations. Risk scores can help guide the decision to perform DFT testing. The subcutaneous ICD represents an area of uncertainty, with limited data available regarding the role of DFT testing in these devices. Current guidelines give a class I recommendation for performing DFT testing at the time of implant. Further studies are needed before this recommendation can be safely dismissed.
Author supplied keywords
Cite
CITATION STYLE
Hayase, J., Do, D. H., & Boyle, N. G. (2018, December 1). Defibrillation threshold testing: Current status. Arrhythmia and Electrophysiology Review. Radcliffe Cardiology. https://doi.org/10.15420/aer.2018.54.2
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.